

## Towards cascading genetic risk in Alzheimer's disease

Andre Altmann<sup>1</sup>, Leon M Aksman<sup>2</sup>, Neil P Oxtoby<sup>1</sup>, Alexandra Young<sup>1</sup>, ADNI\*, Daniel C Alexander<sup>1</sup>, Frederik Barkhof<sup>1,3,4</sup>, Maryam Shoai<sup>3,5</sup>, John Hardy<sup>3,5</sup>, Jonathan M Schott<sup>5,6</sup>

### Abstract

Alzheimer's disease typically progresses in stages, which have been defined by the presence of disease-specific biomarkers: Amyloid (A), Tau (T) and neurodegeneration (N). This progression of biomarkers has been condensed into the ATN framework, where each of the biomarkers can be either positive (+) or negative (-). Over the past decades genome wide association studies have implicated about 90 different loci involved with the development of late onset Alzheimer's disease. Here we investigate whether genetic risk for Alzheimer's disease contributes equally to the progression in different disease stages or whether it exhibits a stage-dependent effect.

Amyloid (A) and tau (T) status was defined using a combination of available PET and CSF biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. In 312 participants with biomarker-confirmed A-T- status, we employed Cox proportional hazards models to estimate the contribution of *APOE* and polygenic risk scores (beyond *APOE*) to convert to A+T- status (65 conversions). Furthermore, we repeated the analysis in 290 participants with A+T- status and investigated the genetic contribution to conversion to A+T+ (45 conversions). Both survival analyses were adjusted for age, sex, and years of education.

For progression from A-T- to A+T-, *APOE*-e4 burden showed significant effect (HR=2.88; 95% CI: 1.70-4.89; P<0.001), while polygenic risk did not (HR=1.09; 95% CI: 0.84-1.42; P=0.53). Conversely, for the transition from A+T- to A+T+, the *APOE*-e4 burden contribution was reduced (HR=1.62 95% CI: 1.05-2.51; P=0.031), while the polygenic risk showed an increased contribution (HR=1.73; 95% CI:1.27-2.36; P<0.001). The marginal *APOE* effect was driven by e4 homozygotes (HR=2.58; 95% CI: 1.05-6.35; P=0.039) as opposed to e4 heterozygotes (HR=1.74; 95% CI: 0.87-3.49; P=0.12).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

The genetic risk for late-onset Alzheimer's disease unfolds in a disease stage-dependent fashion. A better understanding of the interplay between disease stage and genetic risk can lead to a more mechanistic understanding of transition between ATN stages, a better understanding of the molecular processes leading to Alzheimer's disease as well as opening therapeutic windows for targeted interventions.

Author affiliations:

1 UCL Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering & Department of Computer Science, University College London, UK

2 Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

3 UCL Queen Square Institute of Neurology, University College London, UK

4 Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, The Netherlands

5 UK Dementia Research Institute, University College London, UK

6 Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, UK

\* Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or the writing of this report. A complete list of ADNI investigators can be found at:

[http://adni.loni.usc.edu/wpcontent/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

.

**Correspondence to:**

Dr. Andre Altmann

90 High Holborn, 1st Floor

London, WC1V 6LJ

United Kingdom

Email: [a.altmann@ucl.ac.uk](mailto:a.altmann@ucl.ac.uk)

**Running title:** Cascading Genetic Risk in Alzheimer's

**Keywords:** Alzheimer's disease, *APOE*, polygenic risk, longitudinal progression, biomarker

## Introduction

Alzheimer's disease is characterized, on the neuropathological level, by the buildup of two proteins: amyloid plaques and neurofibrillary tangles of phosphorylated tau<sup>1</sup>. Both these pathological features can be observed long before the memory loss and decline in executive function that is characteristic of patients with Alzheimer's disease. Accumulation of the amyloid plaques in the brain predates the clinical symptoms of Alzheimer's disease by two decades<sup>2</sup>, while the spatial distribution of tau tangles reflects more closely the reported cognitive deficits and neurodegeneration<sup>3</sup>.

The amyloid cascade hypothesis postulates that the deposition of the amyloid- $\beta$  protein – the main component of the amyloid plaques – is the cause of Alzheimer's disease, and that neurofibrillary tangles, cell loss, vascular damage and dementia are a direct consequence<sup>4</sup>. In keeping with the amyloid cascade hypothesis, a theoretical framework for the progression of biomarkers during the course of Alzheimer's disease has been developed<sup>5</sup>. Here, amyloid pathology is the first to appear, followed by tau pathology, neurodegeneration and finally cognitive decline. Support for this theoretical framework comes from a number of lines of evidence, including a variety of data-driven modeling approaches based on biomarker data<sup>6–10</sup>. In an attempt to operationalize this, a simplified ATN model has been proposed<sup>11</sup>. The components of the ATN model refer to the status of three different key biomarkers in Alzheimer's disease: amyloid (A), tau (T) and neurodegeneration (N). In this approach, each of the three biomarkers can either be positive or negative. That is, exceeding the centiloid threshold in amyloid PET imaging would place a participant into the A positive (A+) group, while a scan just below the threshold would be considered amyloid negative (A-). One practical advantage (but also a major source of criticism) of this model is that the biomarker status can be assessed using a variety of methods: wet biomarkers (CSF or plasma) or brain imaging (centiloids or visual reads)<sup>12</sup>. Although the progression from A-T-N- to A+T-N- to A+T+N- to A+T+N+ would be the most typical progression in Alzheimer's disease and in keeping with the theoretical framework of biomarker progression, all combinations of biomarker statuses emerge in observational cohorts<sup>13,14</sup>.

Genome-wide association studies (GWAS) have broadened the understanding of the genetic basis of late-onset Alzheimer's disease (LOAD) over the last decades<sup>15</sup>. Initially, these studies were restricted to cases with a clinical diagnosis of Alzheimer's disease and healthy controls<sup>16–18</sup>. Recently, these GWAS have been enriched with participants with a family history of Alzheimer's disease (diagnosis-by-proxy)<sup>19–21</sup>, leading to a drastic increase in sample size

and expanding the set of genetic risk loci for Alzheimer's disease to 90<sup>15</sup>. These loci have been linked to various molecular processes such as immunity, cholesterol processing and endocytosis<sup>22</sup>. Further studies investigated the genetic effects on Alzheimer's disease-related biomarkers ranging from tau and amyloid levels in CSF<sup>23,24</sup>, in the brain<sup>25,26</sup> to MRI-based measures such as hippocampal volume<sup>27</sup> and phenotypes derived from disease progression modeling<sup>28</sup>. The strongest common genetic risk factor for Alzheimer's disease is the e4 allele of the *APOE* gene: carriers of the e4 allele have a 2-4-fold increased risk to develop Alzheimer's disease, while e4 homozygous subjects have an 8-12-fold increased risk<sup>29</sup>. The genetic risk outside the *APOE* region is often summarized using polygenic scores, which have been shown to improve predictions of clinical diagnosis<sup>30</sup> and pathology-confirmed cases<sup>31</sup>. Likewise, the effect of *APOE* as well as the polygenic risk on various imaging and non-imaging biomarkers have been investigated<sup>32-35</sup>, with ongoing work suggesting that risk accumulated along different molecular pathways exerts differential effects on different biomarkers in Alzheimer's disease<sup>35-37</sup>.

For Alzheimer's disease and for other disorders, genetic risk is often considered as a time-invariant constant. That is, genetic risk identified through case-controls studies is assumed to affect both onset and progression. However, as Alzheimer's disease is now understood to unfold in stages, we hypothesized that in line with the amyloid cascade hypothesis and the A/T/N framework that genetic risk in Alzheimer's disease is disease-stage dependent. That is, some genetic risk factors will aid the transition from A- to A+, while other, distinct genetic risk factors will increase the risk to transition from T- to T+.

In this work we explore whether genetic vulnerability to Alzheimer's disease varies with disease stage. Using longitudinal data from the Alzheimer's disease neuroimaging imitative (ADNI) and survival analysis we show that *APOE* contributes to progression from A-T- to A+T-, but only marginally from A+T- to A+T+. Conversely, polygenic risk contributes to the progression from A+T- to A+T+, but not from A-T- to A+T-.

## Materials and methods

### Data

Data used in the preparation of this article were obtained from the ADNI database (<http://adni.loni.usc.edu>). The ADNI was launched in 2003 as a public–private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of the ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease. For up-to-date information, see [www.adni-info.org](http://www.adni-info.org). ADNI study data were accessed through the R-package ADNIMERGE (accessed: 20<sup>th</sup> July 2023).

### Preparation of genetic data

The genetic data preparation followed the procedure described in Altmann *et al.*<sup>32</sup>. The additional genetic data contributed by the ADNI-3 cohort was integrated with the existing data using the same processing pipeline. Briefly, single nucleotide polymorphism (SNP) genotyping data were available for  $n = 2001$  subjects across ADNI phases 1,2, GO and 3. Genotyping was conducted using four different platforms: Human610-Quad, HumanOmniExpress, Omni 2.5 M and Illumina Infinium Global Screening Array v2 (Illumina)<sup>38</sup>. Prior to imputation, we applied subject-level quality control (QC) steps based on call rate (10% cutoff) and concordance between chip-inferred sex and self-reported sex separately for the four genotyping arrays, all subjects were retained. On SNP-level, we conducted standard QC steps ensuring compatibility with the reference panel used for imputation [strand consistency, allele names, position, Ref/Alt assignments and minor allele frequency (MAF) discrepancy (0.2 cutoff)]. Imputation was carried out using the Sanger Imputation Server (<https://imputation.sanger.ac.uk/>) with SHAPEIT for phasing<sup>39</sup>, Positional Burrows-Wheeler Transform<sup>40</sup> for imputation and the entire Haplotype Reference Consortium (release 1.1) reference panel<sup>41</sup>. Data from the four different genotyping platforms were imputed separately. As part of post-imputation QC, multi-allelic variants and SNPs with imputation INFO score  $< 0.3$  were removed and genotype calls with posterior probability  $< 0.9$  were set to missing (i.e., hard called). Following the initial QC, genotypes from the four platforms were merged. Additional information on the imputation and QC process is detailed in Scelsi *et al.*<sup>28</sup> and <https://rpubs.com/maffleur/452627>. Using the merged data, we retained SNPs with  $MAF \geq 1\%$  and genotyping rate  $> 0.9$ .

SNPweights<sup>42</sup> was used to infer genetic ancestry from genotyped SNPs. The reference panel comprised Central European, Yoruba Africans and East Asian samples from HapMap 3<sup>43</sup> and native Americans from Reich *et al.*<sup>44</sup>. For this study, only participants with predicted central European ancestry of 80% or more were retained ( $n=1851$ ). Next, using the imputed and merged data genetic relatedness between central European participants was computed. First, the SNP content was restricted to SNPs with MAF  $\geq 5\%$  and linkage disequilibrium (LD)-pruning was carried out in PLINK v1.9 (`-indep-pairwise 1000 50 0.1`). The genetic relatedness matrix was computed using the remaining autosomal SNPs and the dataset was trimmed to remove subjects with relatedness  $>0.1$  (`-rel-cutoff 0.1`), leading to  $n=1833$  unrelated participants.

## Definition of genetic risk

In this study, we focused on two sources of genetic risk: (1) the risk conferred through the *APOE* gene based on the genetic markers for APOE- $\epsilon 2$  and APOE- $\epsilon 4$  and (2) the polygenic risk conferred by the remaining genome. As described previously<sup>32</sup>, PRSs were computed using the software PRSice v2.1.9<sup>45</sup>. As base GWAS the stage 1 results of the Alzheimer's disease GWAS featuring a clinically defined Alzheimer's disease phenotype was used<sup>18</sup>. For PRS computation, SNPs with MAF  $\geq 5\%$  were considered and SNPs were selected using LD-clumping (1000 KB, R2 of 0.1 and P-value threshold of 1.0) within the ADNI cohort, missing SNPs were simply ignored on subject level (using the setting `-missing SET_ZERO`) and the *APOE* region was excluded (hg19 coordinates chr19 from 44,400,000 to 46,500,000). For this study, we used only the P-value cutoff of  $1.0e-8$  to build the PRS (**Supplementary Table 1**). PRSs were computed for all ADNI participants with genome-wide genotyping data. Of the remaining subjects,  $n=417$  ADNI-1 participants who contributed to the Alzheimer's disease GWAS<sup>18</sup> were excluded from the analysis to ensure independence between training and application dataset for PRS. Thus,  $n=1416$  unrelated participants with central European ancestry were eligible for inclusion into the study.

## Definition of amyloid status

For this project we relied on two modalities to define amyloid status: Amyloid- $\beta$  PET using the  $^{18}\text{F}$ -florbetapir (FBP) and the  $^{18}\text{F}$ -florbetaben (FBB) PET tracer, and CSF measures of amyloid- $\beta$  (1-42) using the Roche Elecsys® immunoassay. We used processed data by ADNI for both modalities. Detailed information on the PET processing is available elsewhere (<http://adni-info.org>)<sup>46</sup>; and information on CSF amyloid- $\beta$ (1-42) processing is detailed in<sup>47,48</sup>. For CSF amyloid- $\beta$ (1-42) we used the cutoff of 880 pg/mL<sup>48</sup> and for amyloid- $\beta$  PET we used the tracer-specific SUVR (whole cerebellum reference) cutoffs of 1.11 and 1.08 for FBP and FBB<sup>49</sup>, respectively.

A participant's visit was labelled as A+ if either the PET result or the CSF result indicated a positive amyloid finding (i.e., in cases where the results were discordant, the visit would be labelled as A+). Visits with only negative amyloid findings were labeled as A- and visits without any information on amyloid (i.e., neither a PET nor a CSF result) were labelled as 'Amyloid missing'.

## Definition of tau status

In keeping with our definition of amyloid positivity we used available data from CSF and PET imaging to define the tau status. More precisely, we used the Phospho-Tau(181P) CSF Roche Elecsys® immunoassay and PET imaging using the  $^{18}\text{F}$ -Flortaucipir tracer. Details on the processing are available elsewhere (<http://adni-info.org>)<sup>47,48,50</sup>. For CSF we used phosphorylated 181P tau (pTau) with a cutoff of 34.61 pg/mL and for tau PET we used the cutoff of 1.42 in the meta temporal ROI comprising amygdala, entorhinal cortex, fusiform gyrus, inferior and middle temporal gyri<sup>51</sup> when normalized to the inferior cerebellar gray matter<sup>52</sup>. Both cut-offs were data-driven: (1) the tau PET cutoff corresponds to a z-score of 2.0 in the cognitively normal participants in ADNI ( $n=506$ ) and is close to the 'high tau' cutoff of 1.43 defined in by Jack Jr *et al.*<sup>53</sup>; (2) the pTau cutoff was set to maximize the Youden's index between CSF pTau and tau PET (at the 1.42 cutoff) in ( $n=502$ ) ADNI participants with concurrent CSF and PET measurements. The same labeling scheme as for amyloid was applied: a visit was labelled as T+ if either the CSF or the PET indicated a positive finding, T- if there were only negative tau findings and 'Tau missing' if neither data on CSF pTau nor on tau PET were available.



## Statistical modeling

We used cox-proportional hazards models to investigate the genetic contribution of progressing from (1) A-T- to A+T- and from (2) A+T- to A+T+. For (1) we included every eligible participant with genetic data and who was A-T- based on their biomarker results as described above. This earliest A-T- visit was considered the ‘start’ visit (i.e., the status of previous visits was ignored). A subject was considered a converter when the available biomarkers indicated A+T- at a later visit. The time of the first A+T- biomarker finding after their initial A-T- visit was used as the conversion time. For non-converters we recorded the last visit where both amyloid and tau biomarker information was available to define the maximum follow-up time. Similarly, for (2) we included every participant with genetic data and who was A+T-. This first A+T- visit was considered the ‘start’ visit. A subject was considered a converter when the available biomarkers indicated A+T+ at a later visit. The time of the first A+T+ biomarker finding after their initial A+T- visit was used as the conversion time. As before, for non-converters we recorded the last visit where amyloid and tau biomarker information was available as their last point of contact.

For the analyses, the cox-proportional hazards model included age at the inclusion visit (i.e., either the A-T- or the A+T- visit), sex, and education. As variables of interest, we further included genetic variables for PRS as well as allele counts of APOE-e2 and APOE-e4. The proportional hazards assumption was tested for each covariate and for the global model using statistical tests and graphical diagnostics based on scaled Schoenfeld residuals. As a measure of overall model performance, the concordance index (C-index) was computed for the (i) full models (ii) models without *APOE*, (iii) models without PRS, and (iv) models without any genetics. Statistical tests were carried out in R (v 4.1.0) using the `survival` (v 3.5.5), `survminer` (v 0.4.9), and `rms` (v 6.8.0) packages.

## Sensitivity analyses

In addition to the two main analyses, we conducted a series of sensitivity analyses addressing the conversion definition, biomarker cutoffs, biomarker source, and polygenic score source.

## Conversion definition

To maximize the available data, we relaxed the requirement for both amyloid and tau biomarker to be available at the same visit to define conversion. As before, both biomarkers at the same time were required to define the ‘start’ visit as either A-T- or A+T-. However, for defining progression from A-T- or A+T-, a single A+ or T+ visit was sufficient, respectively.

## Biomarker cutoffs

We varied the tau PET cutoff from 1.0 to 3.0 standard deviations above the mean in the cognitively normal ADNI participants. Notably, the lowest cutoff resulted in 1.31 and was close to the neuropathologically defined cutoff of 1.29 by Lowe *et al.*<sup>54</sup>. The pTau cutoffs were adjusted accordingly to maximize Youden's index between CSF pTau and tau PET.

## Biomarker source

To maximize data and follow-up time, the main analyses combined data from two biomarker sources: CSF and PET. Additional sensitivity analyses relied exclusively on either CSF biomarkers or PET biomarkers. For this analysis pTau cutoffs were varied in the range from 22 to 31, covering the values of 24.25 and 29.19, which were found to indicate tau PET positivity in Braak III/IV and Braak V/VI regions, respectively<sup>55</sup>. Tau PET cutoffs were varied, as before, from 1.0 to 3.0 standard deviations above the mean in cognitively normal participants (i.e., in the same range as the main analysis).

## Polygenic Score source

To include more SNPs into the PRS, we explored the summary statistics on Alzheimer's Disease and related dementias by Bellenguez *et al.*<sup>21</sup>. We followed the same PRS pipeline as above and applied a p-value threshold of 5.0e-08 (i.e., genome-wide significant) leading to 77 included SNPs (**Supplementary Table 2**).

## Results

Out of 16,401 visits recorded in ADNI, 3789 (23.1%) visits had both amyloid and tau biomarker data available. Concordance between PET- and CSF-based assessment was 80% and 81% for amyloid and tau, respectively. For both survival models we identified around 300 subjects in the ADNI database with both biomarkers available (**Table 1**): 312 individuals were A-T- of whom 65 converted to A+T-. The mean age of the A-T- group was 71.3 (6.65) years and there was an almost equal number of males and females (49.4% females).  $n=290$  individuals were A+T- at any stage, of whom 45 converted to A+T+. The mean age of the A+T- group was 73.2 (6.9), significantly older than the A-T- group (unpaired t-test:  $T=3.50$ ,  $P<0.001$ ). The fraction of females in that cohort was lower compared to the A-T- group (43.8% females), but not at a significant level (chi-square-test; chi-square=1.65;  $df=1$ ;  $P=0.19$ ). The distribution of APOE-e4 alleles (chi-square test; chi-square= 81.1;  $df=2$ ;  $P=2.4e-18$ ) and APOE-e2 alleles (Fisher's exact test;  $P= 0.0004$ ) differed significantly between A-T- and A+T-. There were more APOE-e2 carriers and fewer APOE-e4 carriers in the A-T- group than in the A+T- group. The PRS did not differ between the A-T- and A+T- groups (two-sided t-test;  $t=0.84$ ;  $df=600$ ;  $P=0.39$ ). The cohort with the relaxed conversion criterion showed comparable characteristics (**Supplementary Table 3**).

### APOE-e4 influences progression from A-T- to A+T-

The survival analysis showed a significant contribution by APOE-e4 allele count (HR=2.88; 1.70-4.89;  $P=8.7e-05$ ) but no significant contribution by PRS (HR=1.09; 0.84-1.42;  $P=0.53$ ) (**Fig. 1**). The APOE-e2 allele count directionally favoured a protective effect, but this was not significant (HR=0.73; 0.28-1.86;  $P=0.51$ ). The Cox proportional hazards assumption held for this model (Global Schoenfeld test  $P=0.24$ ) (**Supplementary Fig. 1**). The C-indices align with this pattern: full model (C=0.612), no APOE (C=0.525), no PRS (C=0.611), no genetics (C=0.531). This pattern of associations of APOE and PRS with progression was largely independent of the tau PET and pTau thresholds (**Supplementary Table 4**). Furthermore, using the more relaxed conversion criteria (i.e., confirmed A+ status was sufficient instead of a confirmation of A+T-) yielded more conversions (85 instead of 65) but qualitatively the same result (**Supplementary Fig. 2**), i.e., a significant contribution by APOE-e4 allele count (HR=3.34; 2.14-5.22;  $P=1.0e=07$ ) but not by PRS (HR=1.06; 0.84-1.34;  $P=0.61$ ).

## Polygenic risk affects the progression from A+T- to A+T+

The survival analysis showed a marginally significant contribution by APOE-e4 burden (HR=1.62; 1.05-2.51;  $P=0.031$ ), which was mainly driven by APOE-e4 homozygotes (HR=2.58; 1.05-6.35;  $P=0.039$ ) rather than APOE-e4 heterozygotes (HR=1.74; 0.87-3.49;  $P=0.12$ ) (**Fig. 2**). Furthermore, there was a significant contribution by PRS (HR=1.72; 1.27-2.36;  $P=0.00057$ ). The APOE-e2 allele count again was directionally consistent with a protective effect, but this was not significant (HR=0.41; 0.09-1.78;  $P=0.23$ ). The Cox proportional hazards assumption held for this model (**Supplementary Fig. 3**). The C-indices drop marginally when either *APOE* or PRS are removed from the model: full model (C=0.657), no *APOE* (C=0.634), no PRS (C=0.615), no genetics (C=0.549). Moreover, the association pattern of *APOE* and PRS with progression was largely independent of the tau PET and pTau cutoffs (**Supplementary Table 4**). In addition, education showed a marginally protective association with conversion to A+T+ (HR=0.89; 0.80-0.99;  $P=0.039$ ). Applying the more relaxed conversion criteria (i.e., confirmed T+ status was sufficient instead of a confirmation of A+T+) yielded more conversions (51 instead of 45) but qualitatively the same result (**Supplementary Figure 5**): a significant contribution by PRS (HR=1.62; 1.22-2.17;  $P=0.001$ ) and a marginal contribution by APOE-e4 allele burden (HR=1.56; 1.04-2.35;  $P=0.031$ ).

## Results are independent of PRS source

Using an the alternative PRS with 77 SNPs led to the same observation of a significant effect by APOE-e4 burden on A-T- to A+T- conversion (HR=2.84; 1.68-4.82;  $P=0.0001$ ) and a lack of contribution by the PRS (HR=0.97; 0.77-1.2;  $P=0.80$ ; **Supplementary Fig. 5A**). Conversely, for A+T- to A+T+ conversion, the contribution by APOE-e4 was reduced (HR=1.71; 1.09-2.68;  $P=0.019$ ), where the PRS exhibited a strong contribution (HR=1.59; 1.19-2.13;  $P=0.00163$ ; **Supplementary Fig. 5B**).

## Results are independent of biomarker source

The main analysis combined different biomarker sources to maximize the available data and the observation time for the conversion analysis. Just relying on PET biomarkers alone, only 7.5% of visits (1237 of 16,401) had both biomarkers and it resulted in shorter observation times for A-T- to A+T- conversion (3.62 (sd=1.07) years) and A+T- to A+T+ conversion (2.94 (sd=1.13) years) compared to the main analysis. Relying solely on CSF biomarkers, 19.2% of visits (3155 of 16,401) had both biomarkers. Overall, this led to shorter observation time with

respect to the main analysis for A-T- to A+T- conversion (3.94 (sd=2.7) years) and A+T- to A+T+ conversions (3.6 (sd=2.38) years). Furthermore, relying on a single source of biomarkers led to reduced sample sizes (from around 300 in the main analyses to 70-250 in the sensitivity analyses) and observed conversions (**Supplementary Table 5** and **Supplementary Table 6**). However, despite the reduced statistical power these sensitivity analyses confirmed the pattern observed in the main analysis: APOE-e4 contributed mainly to the A-T- to A+T- conversion, while PRS contributed to the A+T- to A+T+ conversion (**Fig. 3, Supplementary Table 5, Supplementary Table 6**).

## Discussion

This longitudinal survival analysis demonstrated that APOE-e4 plays an important role for the progression from A-T- to A+T-, but *APOE* is only of marginal importance in A+T- participants who progress to A+T+. Conversely, polygenic risk for AD exhibited the inverse pattern: there was no contribution to the progression from A-T- to A+T-, but a significant contribution to faster progression from A+T- to A+T+. This held true for an alternative PRS defined using a different genetic study and involving a larger number of genetic loci. Notably, when assessing covariates, a differential effect of years of education was observed: higher education had no effect (**Fig. 1**) or was marginally harmful (**Supplementary Fig. 2**) for the progression from A-T- to A+T-, but was protective for the conversion from A+T- to A+T+ (**Fig. 2**). The bisection of the genetic risk by disease stage was largely independent of the applied biomarker cutoffs. Moreover, relying on only a single source of biomarkers for defining stage and conversion confirmed the findings of the main analysis despite reduced sample size and observation time.

The finding of a stronger effect of APOE-e4 earlier in the disease progress may explain the observation of stronger genetic effect of APOE-e4 on Alzheimer's disease in the group of 60-80 year-old people compared to people 80 years and older<sup>56-58</sup>. Amyloid deposition occurs 10+ years before other Alzheimer's disease processes<sup>2</sup> and APOE-e4 is the strongest common genetic risk factor for amyloid deposition, then it would be expected for APOE-e4 to exert its maximum effect in younger people. Still, *APOE* remains the strongest risk factor in individuals 80 years and older<sup>57</sup>. Thus, the age-dependent heterogeneity of *APOE* is likely compounded by a survivor bias: individuals with a very late onset despite carrying APOE-e4 may harbor protective variants<sup>59</sup> such as KLOTHO-VS, where a protective effect on amyloid deposition and Alzheimer's disease was only observed in 60-80 year-olds, but not in the 80+ group<sup>56,60</sup>.

The findings from this longitudinal analysis are also in line with previous reports in the ADNI cohort of *APOE* and polygenic risk on amyloid and tau. For instance, cross-sectional amyloid biomarkers in the CSF and in the brain were mainly driven by *APOE*, while cross-sectional CSF tTau and pTau measurements were associated with PRS beyond the *APOE* locus<sup>32</sup>. Moreover, *APOE* was found to predict amyloid status while polygenic risk for Alzheimer's disease improved predictions of diagnosis as well as clinical progression from MCI to Alzheimer's disease above *APOE* alone<sup>35</sup>. These observations extend to plasma markers of tau pathology: PRS (that excluded the *APOE* region) were found to be only associated with plasma p-tau181 in A+ participants<sup>61</sup>. This association between polygenic risk (beyond *APOE*) and CSF tau biomarkers rather than with amyloid and neurodegeneration was

also observed outside of the ADNI study<sup>62</sup>. Polygenic risk (beyond *APOE*) was associated with non-amyloid endophenotypes in a large cohort of people with MCI. This suggests that these variants are more closely linked with neuronal degeneration than with Alzheimer's disease-related amyloid pathology<sup>63</sup>. All these previous studies made the connection between existing amyloid pathology and correlations between polygenic risk and tau pathology using cross-sectional study designs. In a recent longitudinal study of tau PET in the ADNI cohort, higher polygenic risk for Alzheimer's disease was associated with accelerated increase in tau signal in brain and this effect was modulated by amyloid pathology: A+ participants showed a stronger effect of PRS on tau accumulation<sup>64</sup>. Our longitudinal analysis, which combined CSF and PET data to maximize the sample size, confirms these observations and indicates that polygenic Alzheimer's disease risk (outside the *APOE* region) contributes to tau pathology in A+ participants, but has no meaningful contribution in A- participants. The genetic architecture of Alzheimer's disease, as captured by the PRS, involves multiple different pathways, mainly  $\beta$ -amyloid processing, tau, immunity, and lipid processing<sup>18,21</sup>. The employed PRS covers three genes that have been associated with tau binding: *BINI*, *CLU* and *PICALM*. *BINI* mediates Alzheimer's disease risk by modulating tau pathology<sup>65</sup>, and *BINI* risk variants increase tau PET (but not amyloid PET)<sup>66</sup> in an amyloid-dependent fashion<sup>67</sup>. Our observations of an amyloid-dependent effect of the PRS align with these earlier single gene studies. While there are currently no mechanistic analyses that explain the amyloid-dependent effect of *BINI* on tau pathology, recent data from animal models in Alzheimer's disease suggest a state-dependent effect of genetic risk factors related to microglia: Deletion of *Trem2* in mouse models exacerbated tau accumulation and spreading leading to brain atrophy, but only in the presence of existing  $\beta$ -amyloid pathology<sup>68</sup>. Along the same line, physical contact between microglia and plaques as well as a functioning *TREM2* gene are necessary for the appropriate microglia response to amyloid pathology<sup>69</sup>. Thus, defects in *TREM2* can only contribute to neurodegeneration once amyloid pathology has been established. Consequently, other genes contributing to the PRS may also exert their effect in an amyloid-dependent fashion. Our longitudinal analysis presented here is the first to support such a state-dependent genetic risk model in humans, and further fine-grained examination of how the pathways involved in the PRS contribute to sequential disease progression are needed.

The partition of Alzheimer's disease genetic risk into *APOE*-related and polygenic risk beyond *APOE* is a simplification in this analysis. Recent works have linked established Alzheimer's disease risk loci outside *APOE*, such as *CRI*, to amyloid biomarker levels<sup>23</sup>. Conversely, studies of biomarker levels of tau repeatedly highlight the *APOE* locus<sup>23,24</sup>.



However, if being A+ were a pre-requisite to exhibit pathological accumulation of tau, then the strong genetic association with *APOE* in these GWASs would merely reflect the necessary condition rather than a genuine direct molecular process that affects tau levels. The strong dependency of tau levels on established amyloid pathology is supported by mediation analyses in recent cross-sectional<sup>62</sup> and longitudinal<sup>64</sup> studies. Moreover, the known Alzheimer's disease genetic risk variants are contributing differently to molecular pathways<sup>18,21,22</sup>, where each pathway in turn will exercise differential effects on the AD biomarkers including markers for vascular pathology<sup>37</sup>. Therefore, a pathway PRS only comprising genes associated with the regulation of the amyloid precursor protein catabolic process (e.g., Gene Ontology term GO:1902991) may contribute significantly to the conversion from A-T- to A+T-. Likewise, a pathway PRS using only genes known to bind the tau protein (GO:0048156) may exhibit an even stronger association with A+T- to A+T+ conversion than the general PRS employed here.

In addition to the cascading effect of genetic risk in Alzheimer's disease, we also observed a stage-dependent effect of non-genetic risk factors. Education has been shown to have a protective effect against dementia<sup>70</sup>: here we show that higher rates of education do not influence transition to amyloid positivity, but do slow progression from A+T- to A+T+. Consequently, other non-genetic risk factors may show a similarly state-dependent effect on the pathological pathway from A-T- to A+T+ and further neurodegeneration.

The study has several limitations. Firstly, the current analysis was limited to just two biomarkers in Alzheimer's disease:  $\beta$ -amyloid and tau. It would be desirable to include neurodegeneration (N; of the ATN framework) or potentially more fine-grade staging from advanced data-driven disease progression modeling<sup>7</sup>. However, at this point adding further stages would reduce the available sample size. Secondly, we partitioned the genetic risk in Alzheimer's disease into two components: *APOE* and other top variants combined into a single polygenic risk score. Further work should explore a more fine-grained partition of the polygenic risk into individual SNPs or into pathway-PRS<sup>37</sup>. Thirdly, the study population was of central European ancestry, therefore it is unclear whether the findings would generalize to other genetic backgrounds. Finally, although the ADNI cohort is a large cohort, the number of subjects who were eligible for our analysis was reduced due to the requirement of concordant and longitudinal recordings of multiple biomarkers as well as genetics. The available sample size may have limited statistical power to render the estimated hazards ratios significant in some settings. However, the two conversion analyses were based on similar sample sizes (around 300 participants), thus allowing us to make a relative comparison between the genetic



effect (of *APOE* or PRS) under two different, biomarker defined, disease stages. Moreover, uncertainty of the estimated effects may also be increased due to disease heterogeneity in Alzheimer's disease<sup>71-74</sup>, which is likely underpinned by differences in genetic architecture. Thus, analyses in further large longitudinal cohorts are required to confirm the observation of stage-dependent genetic vulnerability in Alzheimer's disease and to uncover more fine-grained associations with Alzheimer's disease subtypes.

In this work we demonstrated, in a simplified setting, that genetic risk for late onset Alzheimer's disease unfolds in a disease stage-dependent fashion. A better understanding of the interplay between disease stage and genetic risk can lead to a better understanding of the molecular processes leading to Alzheimer's disease as well as opening therapeutic windows for targeted interventions and personalized approaches to dementia prevention.

## Data Availability Statement

Data used in the preparation of this article were obtained from the ADNI database (<http://adni.loni.usc.edu>) and are freely available after registration. Analysis scripts are available at [https://github.com/andrealtmann/cascading\\_genetic\\_risk](https://github.com/andrealtmann/cascading_genetic_risk).

## Funding

This study was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an EU Joint Programme - Neurodegenerative Disease Research (JPND) project (see [www.jpnd.eu](http://www.jpnd.eu)). The project is supported under the aegis of JPND through the following funding organizations: United Kingdom, Medical Research Council (MR/T046422/1); Netherlands, ZonMW (733051106); France, Agence Nationale de la Recherche (ANR-19-JPW2-000); Italy, Italian Ministry of Health (MoH); Australia, National Health & Medical Research Council (1191535); Hungary, National Research, Development and Innovation Office (2019-2.1.7-ERA-NET-2020-00008). N.P.O. is a UKRI Future Leaders Fellow (MR/S03546X/1). JMS acknowledges the support of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, Wolfson Foundation, Alzheimer's Research UK, Brain Research UK, Weston Brain Institute, Medical Research Council, British Heart Foundation, and Alzheimer's Association. This research was funded in whole, or in part, by the Wellcome Trust [227341/Z/23/Z]. For the purpose of open access, the author has applied a CC BY-ND public copyright license to any Author Accepted Manuscript version arising from this submission.

## Competing interests

The authors report no competing interests.

## Supplementary material

Supplementary material is available at *Brain* online.

## References

1. Braak H, de Vos RAI, Jansen ENH, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. *Prog Brain Res*. 1998;117:267-285.
2. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med*. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753
3. Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. *Brain*. 2016;139(5):1551-1567.
4. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med*. 2016;8(6):595-608.
5. Jack Jr CR, Knopman DS, Jagust WJ, et al. Update on hypothetical model of Alzheimer's disease biomarkers. *Lancet Neurol*. 2013;12(2):207.
6. Fonteijn HM, Modat M, Clarkson MJ, et al. An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease. *Neuroimage*. 2012;60:1880-1889. doi:10.1016/j.neuroimage.2012.01.062
7. Young AL, Oxtoby NP, Daga P, et al. A data-driven model of biomarker changes in sporadic Alzheimer's disease. *Brain*. 2014;137(Pt 9):2564-2577. doi:10.1093/brain/awu176
8. Donohue MC, Jacqmin-Gadda H, Le Goff M, et al. Estimating long-term multivariate progression from short-term data. *Alzheimer's & Dement J Alzheimer's Assoc*. 2014;10(5 Suppl):S400-10. doi:10.1016/j.jalz.2013.10.003
9. Jernigan BM, Lang A, Liu B, et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease neuroimaging initiative cohort. *Neuroimage*. 2012;63(3):1478-1486.
10. Lorenzi M, Filippone M, Frisoni GB, et al. Probabilistic disease progression modeling to characterize diagnostic uncertainty: application to staging and prediction in Alzheimer's disease. *Neuroimage*. 2019;190:56-68.
11. Jack CRJ, Bennett DA, Blennow K, Carrillo MC, Dunn B. NIA-AA research framework: towards a biological definition of Alzheimer's disease. Published online 2017. [https://www.alz.org/aaic/\\_downloads/nia-aa-draft-11-27-2017.pdf](https://www.alz.org/aaic/_downloads/nia-aa-draft-11-27-2017.pdf)

12. van der Flier WM, Scheltens P. The ATN framework—moving preclinical Alzheimer disease to clinical relevance. *JAMA Neurol.* 2022;79(10):968-970.
13. Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. *Neurology.* 2020;95(1):e46--e58.
14. Ingala S, De Boer C, Masselink LA, et al. Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. *Alzheimer's & Dement.* 2021;17(7):1189-1204.
15. Lambert JC, Ramirez A, Grenier-Boley B, Bellenguez C. Step by step: towards a better understanding of the genetic architecture of Alzheimer's disease. *Mol Psychiatry.* Published online 2023:1-12.
16. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet.* 2011;43(5):429-435. doi:10.1038/ng.803
17. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet.* 2013;45(12):1452.
18. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing. *Nat Genet.* 2019;51(3):414.
19. Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet.* 2019;51(3):404-413. doi:10.1038/s41588-018-0311-9
20. Wightman DP, Jansen IE, Savage JE, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nat Genet.* 2021;53(9):1276-1282.
21. Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet.* 2022;54(4):412-436.
22. Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer's disease. *Nat Neurosci.* 2020;23(3):311-322.

23. Jansen IE, van der Lee SJ, Gomez-Fonseca D, et al. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. *Acta Neuropathol.* 2022;144(5):821-842.
24. Deming Y, Li Z, Kapoor M, et al. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. *Acta Neuropathol.* 2017;133(5):839-856.
25. Yan Q, Nho K, Del-Aguila JL, et al. Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. *Mol Psychiatry.* 2021;26(1):309-321.
26. Ramanan VK, Wang XK, Przybelski SA, et al. Genome-wide association study of tau-PET: Association of variant near NTNG2 with resistance to tau deposition: Neuroimaging: Imaging genetics. *Alzheimer's & Dement.* 2020;16:e044321.
27. Hibar DP, Adams HHH, Jahanshad N, et al. Novel genetic loci associated with hippocampal volume. *Nat Commun.* 2017;8:13624. doi:10.1038/ncomms13624
28. Scelsi MA, Khan RR, Lorenzi M, et al. Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci. *Brain.* 2018;141(7):2167-2180. doi:10.1093/brain/awy141
29. Belloy ME, Napolioni V, Greicius MD. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. *Neuron.* 2019;101(5):820-838. doi:10.1016/j.neuron.2019.01.056
30. Escott-Price V, Sims R, Bannister C, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. *Brain.* 2015;138(12):3673-3684. doi:10.1093/brain/awv268
31. Escott-Price V, Myers AJ, Huentelman M, Hardy J. Polygenic risk score analysis of pathologically confirmed alzheimer disease. *Ann Neurol.* Published online 2017. doi:10.1002/ana.24999
32. Altmann A, Scelsi MA, Shoai M, et al. A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond APOE. *Brain Commun.* 2020;2(1):fcz047.
33. Sabuncu MR, Buckner RL, Smoller JW, et al. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. *Cereb cortex*

- (*New York, NY 1991*). 2012;22(11):2653-2661. doi:10.1093/cercor/bhr348
34. Mormino EC, Sperling RA, Holmes AJ, et al. Polygenic risk of Alzheimer disease is associated with early- and late-life processes. *Neurology*. 2016;87(5):481-488. doi:10.1212/WNL.0000000000002922
  35. Leonenko G, Shoai M, Bellou E, et al. Genetic risk for Alzheimer's disease is distinct from genetic risk for amyloid deposition. *Ann Neurol*. Published online 2019.
  36. Darst BF, Kosciak RL, Racine AM, et al. Pathway-specific polygenic risk scores as predictors of amyloid- $\beta$  deposition and cognitive function in a sample at increased risk for Alzheimer's disease. *J Alzheimer's Dis*. 2017;55(2):473-484.
  37. Lorenzini L, Collij LE, Tesi N, et al. APOE-dependent and-independent polygenic pathways determining early Alzheimer's Disease pathological changes in CSF and MRI. In: *Alzheimer's Association International Conference*. ; 2023.
  38. Saykin AJ, Shen L, Foroud TM, et al. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. *Alzheimer's Dement*. 2010;6(3):265-273. doi:10.1016/j.jalz.2010.03.013
  39. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. *Nat Methods*. 2013;10:5-6. doi:10.1038/nmeth.2307
  40. Durbin R. Efficient haplotype matching and storage using the positional Burrows-Wheeler transform (PBWT). *Bioinformatics*. 2014;30(9):1266-1272. doi:10.1093/bioinformatics/btu014
  41. McCarthy S, Das S, Kretzschmar W, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48:1279-1283. doi:10.1038/ng.3643
  42. Chen CY, Pollack S, Hunter DJ, Hirschhorn JN, Kraft P, Price AL. Improved ancestry inference using weights from external reference panels. *Bioinformatics*. 2013;29(11):1399-1406. doi:10.1093/bioinformatics/btt144
  43. The International HapMap 3 Consortium, Altshuler DM, Gibbs RA, et al. Integrating common and rare genetic variation in diverse human populations. *Nature*. 2010;467:52-58. doi:10.1038/nature09298
  44. Reich D, Patterson N, Campbell D, et al. Reconstructing Native American population history. *Nature*. 2012;488:370-374. doi:10.1038/nature11258

45. Euesden J, Lewis CM, O'Reilly PF. PRSice: Polygenic Risk Score software. *Bioinformatics*. 2015;31(9):1466-1468. doi:10.1093/bioinformatics/btu848
46. Landau SM, Breault C, Joshi AD, et al. Amyloid- $\beta$  Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods. *J Nucl Med*. 2013;54:70-77. doi:10.2967/jnumed.112.109009
47. Bittner T, Zetterberg H, Teunissen CE, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of  $\beta$ -amyloid (1-42) in human cerebrospinal fluid. *Alzheimer's & Dement*. 2016;12(5):517-526.
48. Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer's disease concord with amyloid- $\beta$  PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's & Dement*. 2018;14(11):1470-1481.
49. Royse SK, Minhas DS, Lopresti BJ, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. *Alzheimer's Res & Ther*. 2021;13(1):1-10.
50. Maass A, Landau S, Baker SL, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. *Neuroimage*. 2017;157:448-463.
51. Jack Jr CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimer's & Dement*. 2017;13(3):205-216.
52. Diedrichsen J. A spatially unbiased atlas template of the human cerebellum. *Neuroimage*. 2006;33(1):127-138.
53. Jack Jr CR, Wiste HJ, Algeciras-Schimmich A, et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. *Brain*. 2023;146(5):2029-2044.
54. Lowe VJ, Lundt ES, Albertson SM, et al. Tau-positron emission tomography correlates with neuropathology findings. *Alzheimer's & Dement*. Published online 2019.
55. Leuzy A, Janelidze S, Mattsson-Carlsson N, et al. Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays. *Neurology*. 2021;97(17):e1681--e1694.



56. Belloy ME, Napolioni V, Han SS, Le Guen Y, Greicius MD. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4. *JAMA Neurol.* 2020;77(7):849-862. doi:10.1001/jamaneurol.2020.0414
57. Lo MT, Kauppi K, Fan CC, et al. Identification of genetic heterogeneity of Alzheimer's disease across age. *Neurobiol Aging.* 2019;84:243.e1-243.e9. doi:10.1016/j.neurobiolaging.2019.02.022
58. Jansen WJ, Ossenkuppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA.* 2015;313(19):1924-1938. doi:10.1001/jama.2015.4668
59. Bonham LW, Geier EG, Fan CC, et al. Age-dependent effects of APOE  $\epsilon$ 4 in preclinical Alzheimer's disease. *Ann Clin Transl Neurol.* 2016;3(9):668-677. doi:10.1002/acn3.333
60. Belloy ME, Eger SJ, Le Guen Y, et al. KL\*VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE\*4 carriers. *Neurobiol Aging.* 2021;101:123-129. doi:10.1016/j.neurobiolaging.2021.01.008
61. Zettergren A, Lord J, Ashton NJ, et al. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. *Alzheimer's Res & Ther.* 2021;13:1-10.
62. Kumar A, Janelidze S, Stomrud E, et al.  $\beta$ -amyloid--dependent and--independent genetic pathways regulating CSF tau biomarkers in Alzheimer disease. *Neurology.* 2022;99(5):e476--e487.
63. Louwersheimer E, Wolfsgruber S, Espinosa A, et al. Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. *Alzheimer's & Dement.* 2016;12(8):872-881.
64. Rubinski A, Frerich S, Malik R, et al. Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease. *Ann Neurol.* 2023;93(4):819-829.
65. Chapuis J, Hansmannel F, Gistelinc M, et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. *Mol Psychiatry.* 2013;18(11):1225-1234. doi:10.1038/mp.2013.1
66. Franzmeier N, Rubinski A, Neitzel J, et al. The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. *Nat Commun.* 2019;10(1):1766.



doi:10.1038/s41467-019-09564-5

67. Franzmeier N, Ossenkoppele R, Brendel M, et al. The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster A $\beta$ -associated tau accumulation and cognitive decline. *Alzheimers Dement.* 2022;18(1):103-115. doi:10.1002/alz.12371
68. Lee SH, Meilandt WJ, Xie L, et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by  $\beta$ -amyloid pathology. *Neuron.* 2021;109(8):1283-1301.
69. Wood JI, Wong E, Joghee R, et al. Plaque contact and unimpaired Trem2 is required for the microglial response to amyloid pathology. *Cell Rep.* 2022;41(8).
70. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet.* 2020;396(10248):413-446.
71. Young AL, Marinescu R V, Oxtoby NP, et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun.* 2018;9(1):4273.
72. Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in Alzheimer's disease. *Nat Med.* 2021;27(5):871-881. doi:10.1038/s41591-021-01309-6
73. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: A retrospective study. *Lancet Neurol.* 2011;10(9):785-796. doi:10.1016/S1474-4422(11)70156-9
74. Graff-Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer's disease in the era of biomarkers. *Lancet Neurol.* 2021;20(3):222-234. doi:10.1016/S1474-4422(20)30440-3

## Figure legends




**Figure 1: Hazard ratios for the conversion from A-T- to A+T-.** (A) Forest plot depicting the Hazards Ratios (HR) for all covariates in the model. (B) Estimated survival curves stratified by APOEε4 genotype. (C) Estimated survival curves stratified by PRS percentile (5%, 50%, 95%).




Edu = Years of Educations; APOEε2 = number of APOE2 alleles, APOEε4 = number of APOE4 alleles; PRS = polygenic risk score, scaled to zero mean and unit standard deviation.


**Figure 2: Hazard ratios for the conversion from A+T- to A+T+.** (A) Forest plot depicting the Hazards Ratios (HR) for all covariates in the model. (B) Estimated survival curves stratified by APOEε4 genotype. (C) Estimated survival curves stratified by PRS percentile (5%, 50%, 95%).

Edu = Years of Educations; APOEε2 = number of APOE2 alleles, APOEε4 = number of APOE4 alleles; PRS = polygenic risk score, scaled to zero mean and unit standard deviation.

**Figure 3: Survival curves for PET only and CSF only analyses.** The top row (A-D) is based on results from AT(N) definitions based exclusively on PET biomarkers (amyloid and tau) with a cutoff of 1.45 for tau PET; the bottom row (E-H) relied on CSF biomarkers (ABETA42 and pTAU) with a cutoff of 26 for pTau. The two left columns (A, B, E, F) display the progression probability from A-T- to A+T- stratified by APOEε4 genotype and PRS quantile (5%, 50%, 95%). The two right columns (C, D, G, H) display the progression probability from A+T- to A+T+.







**Table 1: Demographics**

	A-T-			A+T-		
	Total	Stable	Converter	Total	Stable	Converter
<i>n</i>	312	247	65	290	245	45
Age, y (sd)	71.3 (6.65)	71.0 (6.47)	72.2 (7.25)	73.2 (6.9)	73.2 (6.9)	73.1 (6.8)
Sex (%female)	49.4	48.6	52.3	43.8	43.3	46.7
DX (CN/MCI/AD)	195/113/4	150/94/3	45/19/1	118/153/19	100/128/17	18/25/2
Education, y (sd)	16.7 (2.5)	16.6 (2.6)	17.3 (2.2)	16.4 (2.6)	16.6 (2.7)	15.5 (2.4)
Years Follow-up, y (sd)	5.0 (3.1)	4.7 (3.0)	6.4 (3.4)	4.1 (2.6)	3.8 (2.6)	5.6 (2.3)
Time to event, y (sd)	n/a	n/a	4.5 (2.7)	n/a	n/a	4.4 (2.5)
APOE-e4 (0/1/2)	252/57/3	207/40/0	45/17/3	137/119/34	121/99/25	16/20/9
APOE-e2 (0/1/2)	265/46/1	205/41/1	60/5/0	273/17/0	230/15/0	43/2/0
PRS (sd)	0.013 (0.012)	0.013 (0.012)	0.013 (0.011)	0.013 (0.013)	0.012 (0.013)	0.020 (0.011)

DX = diagnosis (cognitively normal [CN]; mild cognitive impairment [MCI]; Alzheimer's Disease (AD)); PRS = Polygenic Risk Score

# Towards cascading genetic risk in Alzheimer's disease

Andre Altmann<sup>1</sup>, Leon M Aksman<sup>2</sup>, Neil P Oxtoby<sup>1</sup>, Alexandra Young<sup>1</sup>, ADNI\*, Daniel C Alexander<sup>1</sup>, Frederik Barkhof<sup>1,3,4</sup>, Maryam Shoai<sup>3,5</sup>, John Hardy<sup>3,5</sup>, Jonathan M Schott<sup>5,6</sup>

1 UCL Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering & Department of Computer Science, University College London, UK

2 Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

3 UCL Queen Square Institute of Neurology, University College London, UK

4 Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, The Netherlands

5 UK Dementia Research Institute, University College London, UK

6 Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, UK

## Corresponding author:

Dr. Andre Altmann

90 High Holborn, 1<sup>st</sup> Floor

London, WC1V 6LJ

United Kingdom

Email: [a.altmann@ucl.ac.uk](mailto:a.altmann@ucl.ac.uk)


\* Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or the writing of this report. A complete list of ADNI investigators can be found at:

[http://adni.loni.usc.edu/wpcontent/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

.


## Supplementary Material

Global Schoenfeld Test p: 0.3001




**Supplementary Figure 1: Testing the Cox Proportional Hazards assumption for the Amyloid model.** Each panel depicts the scaled Schoenfeld residuals for one covariate. The title of each panel states the p-value of the individual Schoenfeld tests. The title of the plot states the p-value of the global Schoenfeld test. None of the p-values are significant (i.e.,  $P < 0.05$ ), therefore the Cox Proportional Hazards assumption holds.






**Supplementary Figure 2: Hazard ratios for the conversion from A-T- to A+.** (A) Forest plot depicting the Hazards Ratios (HR) for all covariates in the model. (B) Estimated survival curves stratified by APOEe4 genotype. (C) Estimated survival curves stratified by PRS percentile (5%, 50%, 95%). Edu = Years of Educations; APOEe2 = number of APOE2 alleles, APOEe4 = number of APOE4 alleles; PRS = polygenic risk score, scaled to zero mean and unit standard deviation.


Global Schoenfeld Test p: 0.605



**Supplementary Figure 3: Testing the Cox Proportional Hazards assumption for the Tau model.** Each panel depicts the scaled Schoenfeld residuals for one covariate. The title of each panel states the p-value of the individual Schoenfeld tests. The title of the plot states the p-value of the global Schoenfeld test. None of the p-values are significant (i.e.,  $P < 0.05$ ), therefore the Cox Proportional Hazards assumption holds.



**Supplementary Figure 4: Hazard ratios for the conversion from A+T- to T+.** (A) Forest plot depicting the Hazards Ratios (HR) for all covariates in the model. (B) Estimated survival curves stratified by APOEe4 genotype. (C) Estimated survival curves stratified by PRS percentile (5%, 50%, 95%). Edu = Years of Educations; APOEe2 = number of APOE2 alleles, APOEe4 = number of APOE4 alleles; PRS = polygenic risk score, scaled to zero mean and unit standard deviation.



**Supplementary Figure 5: Hazard ratios for the PRS with 77 SNPs based on Bellenguez *et al.* (2022).** (A) Forest plot depicting the Hazards Ratios (HR) for all covariates in the model for the A-T- to A+T- conversion. (B) Forest plot depicting the Hazards Ratios (HR) for all covariates in the model for the A+T- to A+T+ conversion. Edu = Years of Educations; APOEe2 = number of APOE2 alleles, APOEe4 = number of APOE4 alleles; PRS = polygenic risk score, scaled to zero mean and unit standard deviation.

### Supplementary Table 1: Genetic variants contributing to the Polygenic Risk Score.

Chr	Position	SNP	A1	A2	Gene	MAF	Weight	P-value
1	207750568	rs679515	T	C	<i>CR1</i>	0.1778	0.1508	1.56E-16
2	127889932	rs6710467	A	G	<i>BIN1</i>	0.1706	0.133	8.96E-12
2	127892810	rs6733839	T	C	<i>BIN1</i>	0.3879	0.1693	4.02E-28
8	27219987	rs73223431	T	C	<i>PTK2B</i>	0.3578	0.0936	8.34E-10
8	27468503	rs867230	C	A	<i>CLU</i>	0.3958	-0.1333	3.49E-17
11	47380340	rs3740688	G	T	<i>SPI1</i>	0.4331	-0.0935	9.70E-11
11	47663049	rs10838738	G	A	<i>MTCH2</i>	0.3348	-0.0871	5.99E-09
11	47915299	rs34467936	G	A	<i>PTPRJ</i>	0.3372	-0.0905	7.89E-09
11	60021948	rs1582763	A	G	<i>MS4A4A</i>	0.3516	-0.1232	1.19E-16
11	85868640	rs3851179	T	C	<i>PICALM</i>	0.3443	-0.1198	5.81E-16
14	92938855	rs12590654	A	G	<i>SLC24A4</i>	0.3402	-0.0906	8.73E-09
19	1047078	rs4147910	G	A	<i>ABCA7</i>	0.1077	0.1488	9.27E-09
19	1050874	rs12151021	A	G	<i>ABCA7</i>	0.3371	0.1071	2.56E-10

Chr: Chromosome; Position: position of the SNP in hg19; A1: effect allele; A2: reference allele; Gene: closest gene; MAF: minor allele frequency in the joint ADNI data ( $n=2001$ ); Weight: beta coefficient from the genome-wide association study (GWAS); P-value: p-value from the stage I GWAS by Kunkle et al. (2019).

## Supplementary Table 2: Genetic variants contributing to the alternative Polygenic Risk Score.

Chr	Position	SNP	A1	A2	Gene	EAF	Weight	P-value
1	161185602	rs4575098	A	G	ADAMTS4	0.2404	0.0539	1.33E-08
1	161217875	rs2070902	T	C	FCER1G	0.2539	-0.0537	1.05E-08
1	207221638	rs6540874	T	C	C4BPA	0.7938	-0.0706	1.70E-12
1	207518704	rs6656401	A	G	CR1	0.1881	0.1253	2.84E-33
2	127042739	rs56049505	T	G	BINI	0.7987	-0.0618	1.14E-09
2	127072128	rs75836995	T	C	BINI	0.7892	0.0816	6.92E-16
2	127072643	rs17014873	A	C	BINI	0.9293	-0.1166	2.36E-13
2	127130409	rs12989701	A	C	BINI	0.1522	0.0802	8.02E-13
2	127133508	rs34546266	A	G	BINI	0.848	-0.0762	2.64E-11
2	127135234	rs6733839	T	C	BINI	0.3891	0.1686	6.48E-90
2	233117495	rs7421448	T	C	INPP5D	0.0968	-0.1091	1.01E-13
2	233160866	rs28459768	A	C	INPP5D	0.5186	-0.0608	1.31E-13
4	993555	rs3822030	T	G	IDUA	0.5712	0.0514	5.04E-10
4	11023507	rs6846529	T	C	-	0.7174	-0.0673	1.25E-13
5	87002714	rs62375397	T	C	-	0.2104	0.0746	8.58E-14
5	87111682	rs2624182	A	G	-	0.7405	0.0517	3.94E-08
5	180201150	rs113706587	A	G	RASGEF1C	0.1103	0.0925	3.38E-12
6	32373621	rs9391858	A	G	TSBP1	0.8475	-0.068	2.79E-09
6	32408571	rs3763312	A	G	BTNL2	0.2036	-0.0708	5.88E-12
6	32713500	rs2858331	A	G	HLA-DQA2	0.5891	-0.0544	8.76E-11
6	32714360	rs3957148	A	G	HLA-DQA2	0.8996	0.1066	7.93E-15
6	41192063	rs9394766	A	G	TREML2	0.7013	0.0616	3.27E-12
6	41272084	rs4714447	T	C	TREM1	0.3449	0.0578	1.73E-11
6	47543755	rs9349413	A	G	CD2AP	0.735	-0.0649	1.61E-12
6	114361563	rs976271	A	G	HS3ST5	0.3613	0.0467	3.24E-08
7	28135367	rs67250450	T	C	JAZF1	0.7875	0.0559	2.02E-08
7	54881563	rs74504435	A	G	-	0.9065	0.0842	2.05E-09
7	100045122	rs4424195	A	G	ZKSCAN1	0.7209	0.057	3.21E-10
7	100176704	rs12705074	A	G	GPC2	0.1121	0.0731	1.80E-08
7	100334426	rs7384878	T	C	PMS2P1	0.69	0.0775	2.13E-18
7	100489836	rs13235951	T	C	NYAPI	0.1266	0.0751	9.56E-10
7	100592493	rs2734895	T	C	FBXO24	0.3128	-0.0586	6.58E-11
7	143413669	rs11771145	A	G	EPHA1	0.3476	-0.0604	1.29E-12
8	27362470	rs73223431	T	C	PTK2B	0.3694	0.0656	5.34E-15
8	27545260	rs7341557	A	G	EPHX2	0.1011	-0.0986	8.78E-13
8	27562086	rs11780834	A	G	GULOP	0.8236	-0.0626	3.42E-09
8	27610986	rs867230	A	C	CLU	0.6031	0.1009	1.50E-33
8	94988691	rs4734295	A	G	NDUFAF6	0.5394	-0.0487	1.98E-09
8	100663356	rs1693551	T	C	SNX31	0.5328	-0.0459	1.79E-08
10	11450869	rs11257101	T	C	USP6NL	0.6898	0.0481	4.69E-08
10	11676714	rs7912495	A	G	ECHDC3	0.5381	-0.0572	2.87E-12
10	60025170	rs7068231	T	G	ANK3	0.4026	-0.0487	6.79E-09
10	80494228	rs6586028	T	C	TSPAN14	0.8036	0.0791	1.33E-14
11	47389337	rs10838702	T	G	SLC39A13	0.4008	0.0565	7.84E-12
11	47759202	rs7927445	T	G	FNBP4	0.3105	0.0498	1.29E-08
11	60254475	rs1582763	A	G	MS4A4A	0.371	-0.086	1.65E-24
11	86095220	rs568755	A	G	PICALM	0.6909	-0.05	1.23E-08
11	86152038	rs56157503	A	C	PICALM	0.8768	-0.0882	7.69E-13
11	86156833	rs10792832	A	G	PICALM	0.3578	-0.1056	6.33E-36
11	121487553	rs60228070	T	C	SORL1	0.8997	-0.0756	2.70E-08

11	121566862	rs1784920	A	G	<i>SORL1</i>	0.1215	-0.0827	1.35E-10
14	39418472	rs74745468	A	G	<i>FBXO33</i>	0.0875	0.0822	1.40E-08
14	52924962	rs17125924	A	G	<i>FERMT2</i>	0.9108	-0.0881	5.82E-10
14	92472511	rs12590654	A	G	<i>SLC24A4</i>	0.3279	-0.0693	2.08E-15
15	49901356	rs2009833	A	G	<i>ATP8B4</i>	0.3683	-0.0478	3.11E-08
15	58753575	rs593742	A	G	<i>ADAM10</i>	0.7052	0.061	1.04E-11
15	63312881	rs16946801	T	C	<i>APH1B</i>	0.6204	0.0622	1.15E-13
16	30022312	rs12325539	T	C	<i>DOC2A</i>	0.6189	0.0567	1.25E-11
16	31143037	rs78924645	A	G	<i>PRSS36</i>	0.2795	-0.0565	7.71E-10
16	81739604	rs12444183	A	G	<i>PLCG2</i>	0.3872	-0.0591	2.21E-12
16	81942226	rs4485362	T	G	<i>PLCG2</i>	0.5396	0.0463	2.00E-08
16	90103687	rs56407236	A	G	<i>FAM157C</i>	0.0693	0.1097	1.28E-11
17	5220566	rs113762960	A	G	<i>SCIMP</i>	0.129	0.0864	7.78E-13
17	44352876	rs5848	T	C	<i>GRN</i>	0.2886	0.0646	1.76E-12
17	45846317	rs12185268	A	G	<i>SPPL2C<sup>a</sup></i>	0.774	0.0536	3.85E-08
17	46107462	rs4510068	T	G	<i>KANSL1<sup>a</sup></i>	0.3938	-0.0546	1.37E-10
17	46720553	rs199456	T	C	<i>NSF<sup>a</sup></i>	0.2123	-0.0593	2.57E-09
17	58363181	rs2680700	T	G	<i>RNF43</i>	0.3755	-0.0482	9.90E-09
17	63476980	rs4292	T	C	<i>ACE</i>	0.617	0.0688	3.47E-16
19	1032690	rs1141534	T	G	<i>CNN2</i>	0.204	0.073	3.65E-11
19	1047079	rs4147910	A	G	<i>ABCA7</i>	0.8995	-0.0977	1.47E-11
19	1050875	rs12151021	A	G	<i>ABCA7</i>	0.3357	0.1055	4.09E-30
19	1085456	rs72975514	T	C	<i>ARHGAP45</i>	0.7924	0.06	4.60E-08
19	1833339	rs732310	T	G	<i>REXO1</i>	0.5158	-0.05	1.33E-08
20	56423488	rs6014724	A	G	<i>CASS4</i>	0.9102	0.1176	4.84E-16
21	26101558	rs2154481	T	C	<i>APP</i>	0.5236	0.05	1.02E-09
21	26775872	rs2830489	T	C	<i>ADAMTS1</i>	0.2809	-0.0547	1.72E-09

Chr: Chromosome; Position: position of the SNP in hg38; A1: effect allele; A2: reference allele; Gene: closest protein-coding gene within 100kb; EAF: effect allele frequency; Weight: beta coefficient from the genome-wide association study (GWAS); P-value: p-value from the stage I GWAS by Bellenguez *et al.* (2022). <sup>a</sup>: *MAPT* locus

### Supplementary Table 3: Demographics (relaxed conversion criterion).

	A-T-			A+T-		
	Total	Stable	Converter	Total	Stable	Converter
N	400	315	85	311	260	51
Age, y (sd)	71.0 (6.9)	70.8 (6.7)	72.1 (7.1)	73.2 (7.0)	73.1 (7.0)	73.5 (7.0)
Sex (%female)	48.0	47.6	49.4	43.1	42.7	45.1
DX (CN/MCI/AD)	229/166/5	174/137/4	55/29/1	131/161/19	112/131/17	19/30/2
Education, y (sd)	16.7 (2.4)	16.6 (2.5)	17.2 (2.2)	16.5 (2.6)	16.6 (2.6)	15.8 (2.4)
Years Follow-up, y (sd)	4.9 (3.0)	4.6 (2.8)	6.3 (3.4)	4.0 (2.7)	3.7 (2.6)	5.5 (2.4)
Time to event, y (sd)	n/a	n/a	4.2 (2.7)	n/a	n/a	4.0 (2.4)
APOE-e4 (0/1/2)	321/76/3	266/49/0	55/27/3	148/126/37	129/103/28	19/23/9
APOE-e2 (0/1/2)	347/52/1	268/46/1	79/6/0	291/20/0	242/18/0	49/2/0
PRS (sd)	0.013 (0.012)	0.013 (0.012)	0.013 (0.011)	0.014 (0.013)	0.013 (0.013)	0.019 (0.012)

DX = diagnosis (cognitively normal [CN]; mild cognitive impairment [MCI]; Alzheimer's Disease (AD)); PRS = Polygenic Risk Score



### Supplementary Table 4: Sensitivity analysis for different Tau PET cutoffs.

	Tau PET	CSF pTau	n	Events	APOE e4	APOE e4/4	PRS
A-T- to A+T-	1.31	32.30	309	62	0.02915643	4.06E-05	0.6499623
	1.34	32.95	310	64	0.01775002	3.55E-05	0.5021401
	1.37	33.57	311	65	0.00726623	2.20E-05	0.4358987
	1.39	34.13	311	65	0.00699722	2.02E-05	0.5160777
	<b>1.42</b>	<b>34.61</b>	<b>312</b>	<b>65</b>	<b>0.00639089</b>	<b>1.81E-05</b>	<b>0.4962599</b>
	1.45	34.82	314	67	0.00904438	1.41E-05	0.5737404
	1.48	35.07	315	67	0.00896343	1.39E-05	0.5734747
	1.51	35.29	315	67	0.00896343	1.39E-05	0.5734747
	1.54	35.53	316	67	0.00885485	1.38E-05	0.5735298
A+T- to A+T+	1.31	32.30	258	46	0.05796633	0.48549513	0.00204043
	1.34	32.95	266	44	0.10834803	0.2154368	0.00084655
	1.37	33.57	271	42	0.06722642	0.04442165	0.00097163
	1.39	34.13	280	43	0.07594692	0.09580913	0.00069806
	<b>1.42</b>	<b>34.61</b>	<b>290</b>	<b>45</b>	<b>0.11930622</b>	<b>0.03939911</b>	<b>0.0005569</b>
	1.45	34.82	290	43	0.18026366	0.02915812	0.00089779
	1.48	35.07	291	39	0.55440604	0.02044481	0.0076896
	1.51	35.29	293	41	0.30800169	0.02089209	0.0048998
	1.54	35.53	296	39	0.37466685	0.02998641	0.00162742

Tau PET: Tau PET threshold based on 1.0 to 3.0 standard deviations (in steps of 0.25) above the mean in cognitively normal participants. CSF pTau: pTau threshold that maximized the Youden's index for the corresponding Tau PET cutoff. n: sample size; Events: number of converters; APOE e4: p-value for APOEe4 heterozygotes; APOE e4/4: p-value for APOEe4 homozygotes; PRS: p-value for the Polygenic Risk Score. Bold font indicates the settings used for the main analysis (i.e., Tau PET cutoff at a z-score of 2.0).

### Supplementary Table 5: Sensitivity analysis using only Tau PET.

	Tau PET	n	Events	APOE e4	APOE e4/4	PRS
A-T- to A+T-	1.31	108	15	0.00256332	0.998414	0.5466185
	1.34	110	17	0.00617315	0.998169	0.375093
	1.37	112	18	0.00194	0.9983591	0.3558922
	1.39	113	18	0.0019078	0.9983644	0.3514293
	1.42	113	18	0.0019078	0.9983644	0.3514293
	<b>1.45</b>	<b>113</b>	<b>19</b>	<b>0.00276536</b>	<b>0.9982344</b>	<b>0.5255481</b>
	1.48	113	19	0.00276536	0.9982344	0.5255481
	1.51	113	19	0.00276536	0.9982344	0.5255481
	1.54	113	19	0.00276536	0.9982344	0.5255481
A+T- to A+T+	1.31	70	9	0.4401025	0.9988313	0.1140501
	1.34	73	8	0.3714046	0.9987921	0.21299683
	1.37	78	9	0.2152745	0.2792531	0.15481342
	1.39	80	7	0.5417669	0.2673798	0.02184563
	1.42	90	13	0.4710315	0.6737454	0.01884522
	<b>1.45</b>	<b>91</b>	<b>13</b>	<b>0.6017861</b>	<b>0.8375521</b>	<b>0.01031391</b>
	1.48	91	10	0.2393688	0.4005217	0.04235292
	1.51	92	11	0.3619229	0.3545669	0.03555231
	1.54	94	12	0.14025	0.1759473	0.00334521

Tau PET: Tau PET threshold based on 1.0 to 3.0 standard deviations (in steps of 0.25) above the mean in cognitively normal participants. n: sample size; Events: number of converters; APOE e4: p-value for APOEe4 heterozygotes; APOE e4/4: p-value for APOEe4 homozygotes; PRS: p-value for the Polygenic Risk Score. Bold font indicates the settings presented in the main analysis (i.e., Tau PET cutoff at a z-score of 1.0).

**Supplementary Table 6: Sensitivity analysis using only CSF pTau.**

	CSF pTau	n	Events	APOE e4	APOE e4/4	PRS
A-T- to A+T-	22	218	28	0.07085586	1.39E-01	0.9051517
	23	229	30	0.14716628	1.96E-01	0.9600861
	24	236	32	0.06568113	1.86E-01	0.6503611
	25	246	35	0.00771617	1.63E-01	0.5129081
	<b>26</b>	<b>257</b>	<b>38</b>	<b>0.01069569</b>	<b>2.81E-04</b>	<b>0.7715454</b>
	27	263	42	0.0045226	2.65E-04	0.9991425
	28	269	43	0.00171823	1.66E-04	0.9664246
	29	276	44	0.00179873	1.40E-04	0.7945879
	30	279	45	0.000537	1.06E-04	0.6305412
	31	286	47	0.00106118	7.44E-05	0.4812926
A+T- to A+T+	22	91	24	0.01928131	0.00271671	0.41947419
	23	99	21	0.13332607	0.05169251	0.51483344
	24	109	20	0.17550508	0.15774646	0.34919713
	25	115	22	0.20414182	0.58489759	0.03751601
	<b>26</b>	<b>121</b>	<b>21</b>	<b>0.34477282</b>	<b>0.38195035</b>	<b>0.0102725</b>
	27	130	17	0.91675502	0.66832828	0.00761942
	28	136	14	0.76128045	0.77591764	0.07535193
	29	145	12	0.42916222	0.93156112	0.02431801
	30	148	12	0.29036457	0.92810651	0.08045729
	31	154	11	0.6390905	0.61806754	0.04685604

CSF pTau: pTau threshold ranging from 22 to 31 pg/ml. n: sample size; Events: number of converters; APOE e4: p-value for APOEe4 heterozygotes; APOE e4/4: p-value for APOEe4 homozygotes; PRS: p-value for the Polygenic Risk Score.